OraSure Technologies is engaged in two principal segments. The first is Co.'s Diagnostics business, which consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary technologies, as well as other diagnostic products. The second segment is Co.'s Molecular Solutions busines, which is operated primarily through its subsidiaries, DNA Genotek Inc., CoreBiome, Inc., Diversigen, Inc. and Novosanis NV. In the Molecular Solutions business, Co. manufactures and sells kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing. The OSUR stock yearly return is shown above.
The yearly return on the OSUR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OSUR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|